Introduction: There is no published data in Nepal regarding the use of gefitinib in patients
with non-small cell lung cancer (NSCLC). Therefore, a retrospective analysis was conducted …

Background: Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor,
represents a new treatment option for patients with advanced non-small-cell lung cancer …

Background: Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) inhibitor
that has activity in non‐small cell lung cancer (NSCLC). Aim: To evaluate the tolerability …

7099 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain,
has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). The clinical …

Gefitinib has modest activity with an overall response rate of 11–18% in patients with
metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following …

Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, is effective in
treating patients with non‐small cell lung cancer (NSCLC) after unsuccessful chemotherapy …

Introduction Treatment options are limited in patients with advanced or refractory non-small
cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor …

Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …

Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …